Geron guides 2026 RYTELO revenue $220-240M; OPEX $230-240M

GERON CORP

2026 RYTELO net product revenue expected $220-240M.
2026 total operating expenses expected $230-240M.
Amended Pharmakon term loan: Tranche B ($75M) and Tranche C ($50M) draw deadlines extended to July 30, 2026.
Implemented strategic restructuring to streamline operations and support RYTELO commercial growth.
Presented new IMerge trial analyses at ASH 2025 reinforcing RYTELO differentiation in LR-MDS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.